Cronkhite-Canada syndrome

Cronkhite-Canada syndrome (CCS) is a rare, non-inherited gastrointestinal polyposis syndrome characterized by the development of numerous polyps throughout the gastrointestinal tract combined with distinctive ectodermal abnormalities. First described by Cronkhite and Canada in 1955, this condition predominantly affects middle-aged to older adults, with a mean age of onset around 60 years. It is slightly more common in males and has been reported more frequently in Japanese populations, though cases occur worldwide. The hallmark features of CCS include diffuse gastrointestinal polyposis (hamartomatous or inflammatory polyps affecting the stomach, small intestine, colon, and rectum, but typically sparing the esophagus) along with the classic ectodermal triad of alopecia (hair loss), onychodystrophy (nail changes including thinning, splitting, or loss of nails), and skin hyperpigmentation (brown macules, especially on the hands, arms, and face). Patients commonly experience chronic watery diarrhea, weight loss, abdominal pain, and dysgeusia (altered taste). Protein-losing enteropathy and malabsorption can lead to significant nutritional deficiencies, hypoalbuminemia, and electrolyte imbalances, which may become life-threatening if untreated. The exact cause of Cronkhite-Canada syndrome remains unknown, and it is considered an acquired rather than hereditary condition. An autoimmune or inflammatory mechanism has been proposed, supported by the observation that some patients respond to immunosuppressive therapy. Treatment is primarily supportive and includes nutritional supplementation, correction of electrolyte abnormalities, and management of diarrhea. Corticosteroids and other immunosuppressive agents (such as azathioprine or anti-TNF therapy) have shown benefit in some patients. Endoscopic surveillance is important due to an increased risk of colorectal cancer. The prognosis is variable; some patients experience spontaneous remission, while others follow a chronic relapsing course with significant morbidity.

Common questions about Cronkhite-Canada syndrome